RecruitingNot ApplicableNCT06361641
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP
Sponsor
University Hospital, Angers
Enrollment
70 participants
Start Date
May 29, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)
- Patient who has not received treatment specific to hemopathy at the time of sampling
- Obtaining the signature of consent to participate in the study
- Patient having consented to be included in the "Malignant Hemopathy" collection of Angers University Hospital and in FIMBANK database
Exclusion Criteria4
- Person not affiliated to a social security scheme or beneficiary of such a scheme
- Patient with another hemopathy or another active cancer at the time of diagnosis
- Minor patient at diagnosis (< 18 years old)
- Patient not capable or without agreement from the guardian or legal representative
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTMonocytes signatures in myeloproliferative neoplasms at diagnosis
The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06361641
Related Trials
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT0532019824 locations
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879163 locations
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346167 locations
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
NCT0666191530 locations
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT0411650247 locations